Microvascular outcomes in type 2 diabetes – Authors' reply

Sophia Zoungas, Hertzel C. Gerstein, Rury R. Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L. Coleman, John Chalmers, Collaborators on Trials of Lowering Glucose (CONTROL) writing group

Research output: Contribution to journalLetter

Abstract

We appreciate Coen Stehouwer and Thomas van Sloten's comments on the clinical relevance of the endpoints in our meta-analysis of individual participant data from the four large trials of more versus less intensive glucose control in patients with type 2 diabetes. The selection of endpoints followed a rigorous, prespecified process that included foremost: consideration of clinical relevance, use of common definitions, standardised ascertainment, and data availability across the trials.
Original languageEnglish
Pages (from-to)580
Number of pages1
JournalThe Lancet Diabetes and Endocrinology
Volume5
Issue number8
DOIs
Publication statusPublished - Aug 2017
Externally publishedYes

Keywords

  • Correspondence
  • reply
  • response
  • type 2 diabetes
  • Microvascular outcomes
  • less intensive glucose control
  • selection of endpoints
  • composite endpoints
  • macroalbuminuria
  • retinopathy

Fingerprint Dive into the research topics of 'Microvascular outcomes in type 2 diabetes – Authors' reply'. Together they form a unique fingerprint.

Cite this